C92.12
Chronic myeloid leukemia, BCR/ABL-positive, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Chronic myeloid leukemia (CML) is a type of blood cancer that originates in the bone marrow, the spongy tissue inside bones where blood cells are produced. The specific ICD-10 code C92.12 refers to a case of CML that is BCR/ABL-positive and has relapsed after initial treatment. When leukemia is in relapse, it means that the disease has returned or worsened after responding to previous therapy. Understanding this condition involves exploring its causes, symptoms, diagnosis process, and available treatment options.
Causes & Symptoms
Clinical Causes: Genetic mutations within the bone marrow cells The presence of the Philadelphia chromosome, which produces the abnormal BCR-ABL protein Inadequate response or resistance to prior therapies Possible exposure to radiation or certain chemicals, though these are less common causes
Key Symptoms: Fatigue and weakness Unintentional weight loss Night sweats Fever without an infection Abdominal discomfort or fullness due to an enlarged spleen Easy bruising or bleeding Bone or joint pain Frequent infections Swollen lymph nodes General feeling of discomfort or malaise
Diagnostic & Treatment
Diagnosis Path: Blood tests to check for abnormal levels of blood cells and the presence of immature cells Bone marrow biopsy to examine marrow activity and cellular composition Cytogenetic analysis to detect Philadelphia chromosome Molecular testing to identify BCR/ABL gene fusion, often through PCR (Polymerase Chain Reaction) Imaging studies like ultrasound or MRI might be used to assess organ enlargement, especially the spleen
Treatment Protocols: Tyrosine kinase inhibitors (TKIs): Medications such as imatinib, dasatinib, or nilotinib are frontline treatments targeting the BCR/ABL fusion protein Allogeneic stem cell transplant: A potential curative approach for eligible patients, involving the replacement of diseased marrow with healthy donor cells Chemotherapy: Used in certain cases to reduce abnormal cell populations Supportive care: Includes blood transfusions, antibiotics, or growth factors to manage symptoms and prevent complications Clinical trials: Emerging therapies and novel agents may be considered based on individual circumstances
Clinical Advice & FAQs
Billing Guidance
Is C92.12 a billable ICD-10 code?
Yes, C92.12 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.12?
Clinical documentation must specify the nature of Chronic myeloid leukemia, BCR/ABL-positive, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference